2024
Early Hypophosphatemia as a Prognostic Marker in Acute Pancreatitis
Stewart C, Adeniran E, Yadav D, Gorelick F, Liddle R, Wu B, Pandol S, Jeon C. Early Hypophosphatemia as a Prognostic Marker in Acute Pancreatitis. Pancreas 2024, 53: e611-e616. PMID: 38696363, DOI: 10.1097/mpa.0000000000002344.Peer-Reviewed Original ResearchLength of stayAcute pancreatitisMultivariate log-linear modelElectronic health records of patientsGastrointestinal-related hospitalizationsRisk factorsHealth records of patientsMultivariate logistic regression modelAssociated with length of stayUnderstanding risk factorsPrognostic markerSerum phosphateLogistic regression modelsCedars-Sinai Medical CenterAssociated with lengthAssociated with ICU admissionHours of admissionOutcome of APRecords of patientsSerum phosphate levelsLonger hospital stayMedical CenterAP admissionsRegression modelsSevere AP
2019
Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
Lowe ME, Andersen DK, Caprioli RM, Choudhary J, Cruz-Monserrate Z, Dasyam AK, Forsmark CE, Gorelick FS, Gray JW, Haupt M, Kelly KA, Olive KP, Plevritis SK, Rappaport N, Roth HR, Steen H, Swamidass SJ, Tirkes T, Uc A, Veselkov K, Whitcomb DC, Habtezion A. Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Pancreas 2019, 48: 1250-1258. PMID: 31688587, PMCID: PMC7282491, DOI: 10.1097/mpa.0000000000001412.Peer-Reviewed Original ResearchConceptsPancreatic diseasePrecision medicineCurrent precision medicine approachesKidney Diseases workshopProspective clinical trialsNational InstitutePrecision medicine approachHealth care systemKidney diseaseRisk factorsClinical trialsFatal illnessMulticenter effortsMedicine approachDiseaseCare systemDisease mechanismsDiabetesPatient data setsMedicinePersonalized medicinePrecision imagingPatientsTherapyIllness
2018
Cigarette toxin 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces experimental pancreatitis through α7 nicotinic acetylcholine receptors (nAChRs) in mice
Alahmari AA, Sreekumar B, Patel V, Ashat M, Alexandre M, Uduman AK, Akinbiyi EO, Ceplenski A, Shugrue CA, Kolodecik TR, Tashkandi N, Messenger SW, Groblewski GE, Gorelick FS, Thrower EC. Cigarette toxin 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces experimental pancreatitis through α7 nicotinic acetylcholine receptors (nAChRs) in mice. PLOS ONE 2018, 13: e0197362. PMID: 29870540, PMCID: PMC5988302, DOI: 10.1371/journal.pone.0197362.Peer-Reviewed Original ResearchConceptsNNK treatmentHuman acinar cellsNicotinic acetylcholine receptorsTrypsinogen activationAcetylcholine receptorsΑ7 nicotinic acetylcholine receptorIndependent risk factorMarkers of inflammationAcinar cellsΑ7nAChR knockout miceΑ7nAChR activationNeutrophil infiltrationWT miceAcute pancreatitisC57BL/6 miceCigarette smokingPancreatic edemaRisk factorsClinical studiesPancreatitisCigarette smokeKnockout miceExperimental pancreatitisΑ7 isoformPyknotic nuclei